Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 216 posts found.

allergan-westport-ireland_web

New breakthrough for CGRP migraine treatments

February 6, 2018
Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical

Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …

News
amgen_flag

FDA clears Amgen’s bone drug for multiple myeloma

January 8, 2018
Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma

Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News
amgen_hq

Kirin Holdings to withdraw from 30 year venture with Amgen, sell shares for $780m

October 31, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Kirin, joint venture, pharma

Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …

News
biocon-ltd-hebbagodi-bangalore-ukif4_web

Mylan and Biocon Neulasta biosimilar knocked back by FDA

October 11, 2017
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical

Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …

News
amgen_hq

CytomX scores deal with Amgen worth potential $1.5bn

October 4, 2017
Research and Development, Sales and Marketing Amgen, biotech, cytomx, drugs, pharma, pharmaceutical

CytomX Therapeutics and Amgen have signed a deal that could be worth a potential $1.5 billion. The agreement will see …

News
humira_abbott_

Five more biosimilar-free years for AbbVie’s megablockbuster

September 28, 2017
Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …

News

FDA approves first-ever biosimilar for cancer treatment

September 15, 2017
Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar

The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …

News
shutterstock_232245868

Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%

September 7, 2017
Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab

An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …

News

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

News

Pfizer’s biosimilar gets a second knock-back from FDA

June 23, 2017
Medical Communications, Sales and Marketing Amgen, Epogen, FDA, Pfizer

Pfizer has been dealt a stinging blow by the FDA, after it received a second complete response letter from the …

News
ovarian_cancer

Breakthrough treatment for ovarian cancer displays promising results

June 5, 2017
Research and Development, Sales and Marketing Amgen, Cancer, ICR, ovarian cancer

A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking …

News
amgen_hq

Amgen hit by major safety blow on osteoporosis drug

May 22, 2017
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB SA

Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved …

News
amgen_hq

Amgen accuses biosimilar producer of ‘massive conspiracy’

March 9, 2017
Medical Communications Amgen, Coherus, Neulasta, biosimilars

Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. …

News

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025